Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. To date,
most patients with HCC are diagnosed at an advanced tumor stage, excluding them from …

Small molecule kinase inhibitors are one of the fastest growing classes of drugs, which are
approved by the US Food and Drug Administration (FDA) for cancer and noncancer …

Purpose: Lenvatinib has shown efficacy in treating radioiodine-refractory differentiated
thyroid cancer (RR-DTC) in the multinational phase III SELECT study; however, it has not …

Irinotecan (SN-38) is a potent and broad-spectrum anticancer drug that targets DNA
topoisomerase I (Top1). It exerts its cytotoxic effects by binding to the Top1-DNA complex …

The identification of Epidermal Growth Factor Receptor (EGFR) mutations in lung
adenocarcinoma has facilitated the development of personalized medicine based on …

Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …

Background Inter-individual response and tolerability profiles associated with available
disease-modifying treatments (DMTs) are an important aspect of the therapeutic decision …

Background The international, phase 3 COMPARZ study demonstrated that pazopanib and
sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell …

Tyrosine kinase inhibitors (TKIs) are designed to specifically target tyrosine kinases that are
overexpressed and/or mutated in cancer tissues. TKIs binding inhibits a number of cell …

We aimed to use physiologically based pharmacokinetic (PBPK) modeling and simulation to
predict imatinib steady‐state plasma exposure in patients with chronic myeloid leukemia …